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This study compared lipids, the product of lipid peroxidation malondialdehyde (MDA), the acute phase reactant high-sensitive C-
reactive protein(hsCRP),endothelin-1(ET-1),P-selectin,intercellularadhesionmolecule-1(ICAM-1),andvascularcell adhesion
molecule-1 (VCAM-1) between healthy controls, subjects with ischemic heart disease (IHD) and type 2 diabetes mellitus (DM)
subjects who did not perform coronary artery bypass graft (CABG) surgery as well as type 2 DM subjects who performed CABG.
HbA1c, lipids, MDA, hsCRP, ET-1, P-selectin, ICAM-1, and VCAM-1 levels were signiﬁcantly higher in the diabetic groups than
in either healthy controls or IHD subjects. In the diabetic groups, there was a negative association among hsCRP and HDL-C.
ET-1, ICAM-1 levels, and TAG were positively correlated, as do the association between P-selectin, VCAM-1, and HbA1c%. Also a
positive relation was found among hsCRP levels and ICAM-1, as well as MDA and ET-1. P-selectin and ICAM-1 were signiﬁcantly
positively correlated. This study indicates that increased level of oxidative stress marker, proinﬂammatory markers, and their
downstream eﬀectors adhesion molecules occur in type 2 DM.
Copyright © 2007 Hala El-Mesallamy et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Cardiovascular (CV) morbidity is a major burden in patients
with type 2 diabetes mellitus (type 2 DM), with endothe-
lial dysfunction as an early sign of diabetic vascular disease
[1] that is related to the presence of a vascular low-grade in-
ﬂammation.Alterationinendothelin-1(ET-1)balanceofthe
endothelium is the key event in the initiation of arterioscle-
rosis [2], via activation of leukocyte adhesion [3], which is
linked to the presence of a vascular inﬂammation. Cellular
adhesion molecules (CAMs), namely intercellular adhesion
molecule-1 (ICAM-1), and vascular cell adhesion molecule-
1 (VCAM-1), are poorly expressed by the resting endothe-
lium, but are upregulated during inﬂammatory atherogen-
esis and may be an index of endothelial activation or even
a molecular marker of early atherosclerosis [4]. Postpran-
dial rises in hyperglycemia can trigger endothelial damage
through increased oxidative stress [5]. Also, type 2 DM is
associated with increased risk for complications following
coronary artery bypass grafting (CABG) surgery, by induc-
ing inﬂammatory vascular dysfunction [6].
Therefore, this study aimed at measuring the levels
of lipids, the lipid peroxidation product malondialdehyde
(MDA), acute-phase reactant high-sensitive C-reactive pro-
tein (hsCRP), ET-1, P-selectin, ICAM-1, and VCAM-1
among healthy controls and ischemic heart disease (IHD)
subjects, type 2 DM subjects who did not perform CABG
surgery,aswellastype2DMsubjectswhoperformedCABG.
In addition to evaluating if ET-1 and CAMs may be upregu-
latedduringinﬂammatoryatherogenesis,anindexofinﬂam-
matory endothelial activation may be better than assessment
of the conventional CV risk factors. Moreover, the present
work primarily aimed to study the interactions between type
2 DM and susceptibility of lipoproteins to oxidation, and
their relation to inﬂammation. Since it is well known that
type 2 DM subjects have multiple risk factors that potentiate
each other, we limit our study to nonsmoker male diabetic
individuals.
2. SUBJECTS AND METHODS
2.1. Subjects
The studied groups included (57) males, of which (12)
m a l e ss e r v e da sh e a l t h yc o n t r o l s( g r o u pI ) .T h ec o n t r o l
groupwasselectedfromsubjectsthatattendedtheoutpatient2 Mediators of Inﬂammation
endocrine clinic at Ain Shams University Specialized Hospi-
tals (ASUSH). None of the healthy controls, take any med-
ication or dietary supplements including vitamin(s) and/or
antioxidant(s). Forty ﬁve males were selected from patients
admitting to ASUSH Cardiology Department. After proto-
col approval, the study was conducted in the period from
September 2004 to May 2005. Patients in the study were clas-
siﬁed into the following groups: ischemic heart disease sub-
jects without DM (group II) (n = 15), type 2 DM sub-
jects who did not perform CABG (group III) (n = 15),
and type 2 DM subjects who performed CABG surgery not
less than one year (group IV) (n = 15). All subjects gave
written informed consent prior to participation and the
study was approved by the Committees on Medical Ethics
of the ASUSH. The study was carried out in accordance
with the regulations and recommendations of the Declara-
tion of Helsinki. A detailed medical history and drug treat-
ment(s) were collected for all subjects. The following exclu-
sion criteria were used for all subjects: age more than 65
or less than 40 years, acute and chronic inﬂammatory dis-
eases, liver disease, macroalbuminuria, not having recently
received any anti-inﬂammatory drugs. After analysis of ei-
ther diabetic or nondiabetic people, if each one fulﬁlled the
criteria to participate either in the control or in the diabetic
groups,aninvitationwasgivenbyoneoftheauthors.Hyper-
tension was deﬁned as history of arterial hypertension with
or without antihypertensive treatment and/or > 130mm Hg
systolic and/or > 80mm Hg diastolic arterial blood pres-
sure (mean of 3–5 repeated blood pressure measurements).
BMI was calculated as an index of the weight in kilograms
divided by the square of the height in meters. All subjects
were asked to discontinue taking aspirin, if they were us-
ing it, at least two weeks prior to blood collections. Inclu-
sion criteria include type 2 DM of 10–15 years duration, cri-
teria for type 2 DM patients include age at diagnosis > 35
years.
2.2. Laboratoryprocedures
Allsubjectswereadvisedtotakenomedicationonthemorn-
ing before blood sample collection. Initially, fasting blood
samples (5–10mL) were taken between 8 : 00 and 10 :
00 a.m. Blood was obtained from the anticubital vein, af-
ter an overnight fasting period. Samples were divided into
two parts; one containing Na2-EDTA (ﬁnal concentration
1mg/mL) for glycosylated hemoglobin HbA1c% determina-
tion by Stanbio Glycohemoglobin (USA) [7]. The other part
was taken into vacutainer clotted tubes, where sera were ob-
tained by centrifugation at 3000rpm at 4◦C for 10 min-
utes. Sera were separated, aliquoted ﬁrst for the measure-
ment of fasting blood glucose (FBG) [8] and lipids (total
cholesterol (TC) [9] and triacylglycerol (TAG) [10]) by us-
ing standard enzymatic techniques. HDL-C was determined
after precipitation of apolipoprotein B-containing lipopro-
teins [11], and ﬁnally LDL-C was calculated according to the
Friedwald formula (FF) : LDL-C = TC-TAG/5 (mg/dL) [12].
The reference values for the lipid proﬁle were according to
established guidelines [13].
2.3. Analyticaldeterminations
2.3.1. MDAdeterminations
Oxidative susceptibility of LDL was measured as the level of
MDA [14].
2.3.2. CRP,ET-1,andCAMsdeterminations
S e r u ma l i q u o t sw e r ek e p tf r o z e na t−70◦C for hsCRP, ET-1,
P-selectin, ICAM-1, and VCAM-1. ELISA procedures were
carried out according to the manufactures instructions.
2.4. Statisticalanalysis
All statistical analyses were performed using SPSS version 9
software package. Data are presented as mean ± SD if nor-
mally distributed, and as median (with the 25th and 75th
centiles-quartiles) if not normally distributed (FBG, MDA,
hsCRP, ET-1, and CAMs). To determine diﬀerences between
groups, analysis of variance (ANOVA) followed by Bonfer-
roni’s post-hoc analysis was used for multiple comparisons
between diﬀerent groups. When comparing normally dis-
tributed variables between patients and healthy controls, an
independent t test was used for comparing means. For com-
parison of skewedly distributed variables between the study
groups, median values were calculated and Mann-Whitney
U test was used. The Kruskall-Wallis test for multiple inde-
pendent samples was used for comparison between the sub-
groups of patients. Correlations between type 2 DM, CV risk
factors, and CRP were evaluated by Spearman’s rank corre-
lation. Multiple linear regressions including all participants
wereusedtoevaluatewhetherestablishedtype2DMandCV
risk factors independently predicted the levels of CRP, ET-
1, and CAMs. Type 2 DM groups were also introduced into
thismodeltogetherwithage,BMI,HbA1c,hypertension,and
lipids to evaluate if the observed diﬀerences in CRP, ET-1,
CAMsbetweentype2DMpatientsandhealthycontrolswere
independent of the inﬂuence of CV risk factors. The level of
statistical signiﬁcance was set at P ≤ .05.
3. RESULTS
The baseline characteristics of the studied participants are
presented in Table 1. The groups did not diﬀer in relation to
sex, smoking, and nutritional status as indirectly evaluated
by blood (red and white) cell analysis (not shown). Type 2
DM patients (groups III and IV) were overweight, whereas
the control group presented normal values (P<.01). Inas-
much, HbA1c levels in type 2 DM patients were higher than
either those in the control group or the IHD group (P<
.01). FBG mg/dL levels increased signiﬁcantly in the diabetic
groups III, IV when compared with either the control vol-
unteer or the ischemic group (Table 1). Other characteristics
of the groups are depicted in Table 1 (age, systolic, and di-
astolic blood pressure). Lipids proﬁle (TAG, TC, and LDL-C
levels, as well as the CV risk ratio TC/HDL-C) in the diﬀer-
ent studied groups (ANOVA, Table 1) were signiﬁcantly in-
creased in groups II, III, and IV when compared with theHala El-Mesallamy et al. 3
Table 1: Clinical and laboratory characteristics of the studied groups; healthy controls (group I), ischemic heart disease (group II), type
2 DM who did not perform CABG (group III), and type 2 DM who performed CABG (group IV). Data are mean ± SD. n = number of
subjects, SBP = systolic blood pressure, DBP = diastolic blood pressure, BMI = body mass index, FBG = fasting blood glucose.
Parameters Group I Group II Group III Group IV
n 12 15 15 15
Age (years) 45 ± 15 3 ± 5(a) 52 ± 4(a) 55 ± 5(a)
SBP (mm Hg) 104 ± 5 129 ± 17(a) 143 ± 12(a, b) 147 ± 13(a, b)
DBP (mm Hg) 73 ± 68 6 ± 11(a) 93 ± 5(a) 92 ± 7(a)
BMI (Kg/m2) 24 ± 12 5 ± 1(a) 32 ± 1(a, b) 31 ± 3(a, b)
FBG (mg/dL) §§ 106 (99–114) 108 (80–140) 255 (225–277)(a, b) 229 (220–249)(a, b)
HbA1c(%) 6 ± 16 ± 19 ± 1(a, b) 9 ± 1(a, b)
TAG (mg/dL) 141 ± 26 204 ± 27(a) 256 ± 45(a, b) 283 ± 59(a, b)
TC (mg/dL) 201 ± 6 242± 13(a) 405 ± 53(a, b) 373 ± 53(a, b)
HDL-C (mg/dL) 45 ± 33 2 ± 3(a) 22 ± 4(a, b) 21 ± 5(a, b)
LDL-C (mg/dL) 127 ± 11 169 ± 16(a) 332 ± 51(a, b) 296 ± 56(a, b)
TC/HDL-C 4 ± 0.3 8 ± 1(a) 19 ± 3(a, b) 19 ± 4(a, b)
§§ = median (with the 25th and 75th centiles-quartiles).
(a, b, c) Signiﬁcant diﬀerence from healthy controls, IHD group, type 2 DM group who did not perform CABG, respectively, at P ≤ .01.
Table 2: Serum concentrations of the studied parameters in healthy controls (group I), ischemic heart disease (group II), type 2 DM who
did not perform CABG (group III), and type 2 DM who performed CABG (group IV). Values are median (with the 25th and 75th centiles-
quartiles).
Groups/parameters Group I Group II Group III Group IV
n 12 15 15 15
MDA (nmol/mL) 1 (0-1) 4 (1–4)(a) 9 (7–13)(a,b) 10 (9–12)(a,b)
hsCRP (mg/L) 0.4 (0-1) 3 (2–4)(a) 9 (8–10)(a, b) 10 (9–11)(a,b)
ET-1 (pg/mL) 3 (1–3) 2 (2–4) 10 (9–18)(a,b) 10 (9–12)(a, b)
P-selectin (ng/mL) 67 (60–110) 52 (14–137) 95 (48–212)(a) 98 (84–155)
ICAM-1 (ng/mL) 140 (107–194) 236 (153–284)(a) 367 (246–449)(a,b) 473 (429–512)(a,b)
VCAM-1 (ng/mL) 608 (388–848) 625 (247–944) 1167 (987–1284)(a,b) 977 (840–1244)(a,b)
(a, b, c) Signiﬁcant diﬀerence from healthy controls, IHD group, type 2 DM group who did not perform CABG, respectively, at P ≤ .05.
control group I, except for HDL-C which was decreased in
these groups compared with the control group I.
As shown in Table 2, the median values of MDA, hsCRP,
ET-1, ICAM-1, and VCAM-1 concentrations were signiﬁ-
cantly higher in the IHD group and the diabetic groups
(groups III, IV) in comparison to those levels obtained in the
control group (P ≤ .05). On the other hand, no signiﬁcant
diﬀerences among the diabetic groups (groups III, IV) were
observed in all parameters.
After adjustments for established CV risk factors, be-
ing a type 2 DM patient (group III: type 2 DM who did
not perform CABG and group IV: type 2 DM who per-
formed CABG) was still an independent statistically signif-
icant predictive factor for CRP, ET-1, and P-selectin levels
(P ≤ .05), but not for MDA, ICAM-1, and VCAM-1, where
hsCRP, ET-1, and P-selectin levels were all dependent on
MDA levels (P ≤ .05). Also, P-selectin was dependent on
HbA1c%.
In the diabetic groups (groups III, IV) (n = 30), a nega-
tive association was found among hsCRP levels and HDL-
C concentrations (Figure 1(a)). ET-1 levels and TAG con-
centrations were positively correlated, as did the relation
between P-selectin and HbA1c%, ICAM-1 and TAG, and
the association between VCAM-1 and HbA1c (Figures 1(b),
1(c), 1(d),a n d1(e)). Also in the diabetic groups (groups III,
IV) (n = 30), a positive association was observed among
MDA values and ET-1 determinations and among hsCRP
levels and ICAM-1 determinations (Figures 2(a) and 2(b)).
P-selectin and ICAM-1 were signiﬁcantly positively corre-
lated (Figure 2(c)).
4. DISCUSSION
Data in this study demonstrate that MDA, hsCRP, Lipids
(TAG, TC, and LDL-C), ET-1, and CAMs increased in type
2 DM patients, together with decreased HDL-C levels. These
results conﬁrm reports in the literature that a low-grade in-
ﬂammation exists in type 2 diabetic patients. Atherosclero-
sis is a multifactorial disease and evidence indicates that cer-
tain synergistic risk factors accelerate atherogenesis. When
raised TAG coexists with an atherogenic cholesterol proﬁle,
the overall risk is enhanced [15]. Impairment of vascular en-
dothelial function is an initial step in the development of in-
ﬂammatory atherosclerosis [16].4 Mediators of Inﬂammation
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Figure 1: Correlation between (a) hsCRP (mg/L) and HDL-C (mg/dL), (b) ET-1 (pg/mL) and TAG (mg/dL), (c) P-selectin (ng/mL) and
HbA1c(%), (d) ICAM-1 (ng/mL) and TAG (mg/dL), and (e) VCAM-1 (ng/mL) and HbA1c(%) in type 2 DM patients (groups III and IV)
(n = 30). Each individual value is represented by a symbol (), r = Spearman’s rank correlation coeﬃcients.
The mechanism of the elevation of CAMs may be
contributed to hyperglycemia, hyperinsulinemia, oxidative
stress, inﬂammation, and insulin resistance [17]. Endothe-
lial dysfunction, as it relates to both ET-1 and CAMs, might
be considered not at the level of EC activation, leukocyte ag-
gregation, and activation, but rather at the point where in-
ﬂammatory oxidative stress is increased. The earliest event
following plaque ﬁssure is the adhesion and aggregation of
platelets leading to thrombus formation. Increased platelet
aggregation, in response to inﬂammation, contributes to the
development of atherosclerosis and increases the risk of my-
ocardial infarction [18]. In our study, the level of MDA in
serum was found to be higher in diabetic patients (groups
III, IV) than in control subjects (groups I, II) as well as being
associated with lipids and ET-1 positively. This conﬁrms that
in atherosclerotic plaque activated macrophages and neu-
trophils release several kinds of oxidants, which in high con-
centrations lead to oxidative stress causing damage to lipids.Hala El-Mesallamy et al. 5
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Figure 2: Correlation between (a) MDA (nmol/mL) and ET-1
(pg/mL), (b) hsCRP (mg/L) and ICAM-1 (ng/mL), (c) P-selectin
(ng/ml) and ICAM-1 (ng/mL) in type 2 DM patients (groups III
and IV) (n = 30). Each individual value is represented by a symbol
(), r = Spearman’s rank correlation coeﬃcients.
Furthermore, the ﬁndings of raised levels of hsCRP in dia-
betic patients are in accordance with that the inﬂammatory
course of the atherosclerotic process is more severe in dia-
betic patients than in nondiabetic subjects [19]. Taken to-
gether, these ﬁndings suggest that these groups of diabetic
patients present a low-grade inﬂammation triggered by the
diabetic mellitus state, which is favoring the progression of
accelerated atherosclerosis. In agreement with this, our study
found that hsCRP is not a surrogate marker for CVD in dia-
betic patients. However, further studies are needed to better
evaluatetheoutcomeofthediabeticsubgroupthatpresented
high levels of CRP. Recently, Schulze et al. [20] reported that
high plasma levels of CRP were associated with an increased
risk of CV events among diabetic men, independent of cur-
rently established lifestyle risk factors, blood lipids, and gly-
caemic control [20]. Regarding the present study, one cannot
rule out the possibility that the presence of obesity, signiﬁ-
cant hyperglycaemia, and the low levels of HDL-cholesterol
in the diabetic group may have contributed to these results.
In addition, the ﬁnding that serum levels of both CRP and
HDL-C are negatively correlated provides a further indica-
tion that both variables contribute to the vascular inﬂamma-
tory process. Several CV disorders, including atherosclerosis,
are associated with endothelial dysfunction [21], as well as
enhanced expression of CRP and ET-1. The higher incidence
ofatheroscleroticvasculardiseaseinpatientswithtype2DM
may also be related to the atherogenic properties of ET-1
[3]. P-selectin level tended to be higher in type 2 DM sub-
j e c t sc o m p a r e dw i t hg r o u p sIa n dI I ,b u tt h i sd i ﬀerence did
not achieve statistical signiﬁcance. This result may be ex-
plained by the diﬀerent patterns of CAMs expression in var-
ious cell types and tissues. Activated platelets play an impor-
tantroleincoagulationandreleaseofP-selectin[22].ICAM-
1 is mostly expressed in endothelial cells (ECs) and their ex-
pression is enhanced by a variety of proinﬂamatory stimuli
[23].
Diabetes is associated with increased risk for complica-
tions following CABG surgery, as the vasoconstrictor ET-1
is elevated in diabetic patients, following CABG [6]. Tis-
sue damage after ischemia reperfusion involves leukocyte en-
dothelial interactions mediated by CAMs [24]. Augmented
superoxide production plays an important role in diabetic
complications by causing vascular dysfunction. A recent
study showed that platelets from patients after CABG show
an increased expression of P-selectin, a marker of α-granule
secretion associated with the progression of atherosclerosis
[25]. Accordingly, our study investigated ET-1 and CAMs
levels in type 2 DM patients who performed CABG (group
IV). Hyperlipidemia is an important pathogenic mechanism
of inﬂammatory endothelial dysfunction in patients with
type2DM.Inthisstudy,lipidsproﬁle,MDA,CRP,ET-1,and
CAMs levels were elevated, and correlated in type 2 DM pa-
tients who performed or did not perform CABG. Hence, in-
creased endothelial activity, in this study is related and corre-
lated to hyperglycemia, dyslipidemia, and inﬂammation ob-
served in these groups, suggesting that type 2 DM-associated
metabolic disorders can explain the signiﬁcant impairment
of endothelial function and CAMs. Spearman’s correlations
showed that P-selectin and VCAM-1 were signiﬁcantly posi-
tively correlated to HbA1c, while ET-1 and ICAM-1 were cor-
r e l a t e dt oT A Gi ng r o u p sI I Ia n dI V( n = 30). Also P-selectin
was correlated positively signiﬁcantly with ICAM-1. The di-
rect correlation with HbA1c suggested that elevated glucose
concentrations were responsible for endothelial activation6 Mediators of Inﬂammation
and that hyperglycemia increases CAMs, which reﬂects ex-
cessive formation of atherosclerotic plaques in patients with
disturbancesofglucosemetabolism[26].Thedirectrelation-
ship with plasma lipoproteins could suggest that hyperdys-
lipidemia aﬀects CAMs secretion in vivo. Thus CRP, ET-1,
P-selectin, ICAM-1, and VCAM-1 levels are related to both
hyperglycemiaanddyslipidemiaandmayreﬂectthepresence
of a multiple-risk factor clustering syndrome providing fur-
ther support for the role of these markers in atherosclerosis.
Taken together, these data strongly suggest that type 2 DM-
associatedmetabolicdisorderscanexplainthesigniﬁcantim-
pairment of endothelial function and CAMs.
5. CONCLUSIONS
Our study shows that hsCRP, ET-1, and CAMs as surrogate
markers of CV inﬂammation are elevated in diabetic pa-
tients.Takentogether,thesedatasupporttheopinionthatdi-
abeticpatientspresentahighriskforCVDandneedearlyag-
gressive intervention. Increased oxidative stress and inﬂam-
mation in type 2 DM could be partly overcome by antioxi-
dant administration.
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